Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 6/20 | 0.51 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 3/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7338467 | 0.87 | PREP (0.44) | L3MBTL1HPGDSMN1; SMN2NPC1PREP | |
| SCHEMBL8693803 | 0.86 | KMT2A (0.51) | L3MBTL1HPGDSMN1; SMN2NPC1PREP | |
| SCHEMBL2848014 | 0.85 | MAPT (0.49) | L3MBTL1NPC1PREPMMP1MAPT | |
| SCHEMBL5032713 | 0.84 | GSK3B (0.59) | PREPALDH1A1GSK3B | |
| SCHEMBL1508129 | 0.80 | ALDH1A1 (0.48) | L3MBTL1SMN1; SMN2NPC1PREPMMP1 | |
| SCHEMBL2500559 | 0.80 | ELANE (0.52) | HPGDPREPMAPT | |
| SCHEMBL19020169 | 0.79 | PREP (0.41) | SMN1; SMN2NPC1PREPMAPTHDAC3 | |
| SCHEMBL8008283 | 0.79 | NPC1 (0.57) | NPC1MAPT | |
| SCHEMBL6542930 | 0.78 | CA1 (0.52) | HPGDSMN1; SMN2PREPALDH1A1 | |
| SCHEMBL936407 | 0.78 | MAPT (0.53) | STSL3MBTL1HPGDSMN1; SMN2PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-3807263-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | Amphista Therapeutics Ltd (GB) | 2021-04-21 | — | — | EP | disclosed |
| CN-112585127-A | Bifunctional molecules for targeting Uchl5 | 安菲斯塔治疗有限责任公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2019238886-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING USP14 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238816-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UCHL5, UCHL3, UCHL1 | STS 3917/4885HSD17B3 3389/4885L3MBTL1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.